--- title: Product Overview --- [![FAScinate-Logo](https://www.fascinatetherapeutics.com/hs-fs/hubfs/FAScinate-Logo.png?width=995&height=296&name=FAScinate-Logo.png "FAScinate-Logo")](http://fascinatetherapeutics.com) Search - [About Us](https://www.fascinatetherapeutics.com/about-us) - [Product Overview](https://www.fascinatetherapeutics.com/product-overview) - [Partnerships](https://www.fascinatetherapeutics.com/partnerships) - [News/Publications](https://www.fascinatetherapeutics.com/news) # Product Overview ## First-in-class Drug Candidate that Could Halt the Progression of Parkinson’s Parkinson’s disease (PD) is the second most common neurodegenerative condition. It progresses gradually, but inevitably—causing the death of dopaminergic neuron cells, which impacts the motor system and continually degrades patients’ quality of life. Current drugs help address the symptoms of PD, but do nothing to stop its progression. That changes with drug candidate KM-819. ## How KM-819 Protects Cells from Parkinson’s Our drug candidate slows and even stops the progression of PD by protecting dopaminergic neurons. It accomplishes this by inhibiting the FAF1 proteins that promote cell death—an approach we’ve shown to be effective in animal models and are beginning to test in human proof of concept trials. ### Unique Opportunities with KM-819 **New Target & Mechanism** KM-819 is the first disease modifying drug candidate for PD that targets and inhibits FAF1 proteins. **Neuroprotection** Where other PD treatments focus on addressing the symptoms of cell death, KM-819 prevents the cells from dying in the first place, slowing or even stopping progression altogether. **Excellent Safety Profile** KM-819 has completed long-term safety toxicology and a phase I clinical study, demonstrating an acceptable safety profile for long-term administration in patients. ![New-picture-2 2](https://www.fascinatetherapeutics.com/hubfs/New-picture-2%202.jpg) ## The Future of Parkinson’s Treatment With phase I clinical trials and the long-term animal toxicology study completed, KM-819 now moves into phase II trials. That brings us one step closer to creating a brighter future for PD patients everywhere. [PARTNER WITH FASCINATE](https://www.fascinatetherapeutics.com/partnerships) [![footer-logo](https://www.fascinatetherapeutics.com/hs-fs/hubfs/footer-logo.png?width=996&height=297&name=footer-logo.png "footer-logo")](https://www.fascinatetherapeutics.com/) ##### Quick Links - [Product Overview](https://www.fascinatetherapeutics.com/product-overview) - [About Us](https://www.fascinatetherapeutics.com/about-us) - [Partnerships](https://www.fascinatetherapeutics.com/partnerships) - [News](https://www.fascinatetherapeutics.com/news) #### Contact Us FAScinate Therapeutics 4365 Executive Dr. Ste. 660 San Diego, CA 92121 [(858) 630-8540](tel:+18586308540) [contact@fascinatetherapeutics.com](mailto:contact@fascinatetherapeutics.com) © FAScinate Therapeutics 2026 | All rights reserved.